W26--Best Abstracts in Endocrinology

Friday, October 24, 2025

10:15 AM - 12:15 PM PDT

Location:Ballroom 1

Chair(s)

This session highlights some of the most exciting new research in CF endocrinology and reproductive health. Five topics will be presented.

To discuss the effects of ETI therapy on bone mineral density, lean mass, and testosterone levels
To review alternative cystic fibrosis related diabetes (CFRD) screening tests
To examine current effects of pregnancy and early parenthood on CF health

10:15 AM - 12:15 PM PDT

W26.1- Bone Mineral Density in Young Children with Cystic Fibrosis Pre- and Post-Elexacaftor/Tezacaftor/Ivacaftor – The BEGIN Study
Speaker: Meghan Shirley Bezerra, PhD – Children's Hospital of Philadelphia
10:15 AM - 12:15 PM PDT

W26.2- Baseline lean mass deficits in adolescents and adults with CF persist 24-30m following elexacaftor/tezacaftor/ivacaftor initiation
Speaker: Marissa Kilberg, MD, MSEd – Children's Hospital of Philadelphia
10:15 AM - 12:15 PM PDT

W26.3- Evaluation of testosterone levels in males with Cystic Fibrosis before and after initiation of Elexacaftor/Tezacaftor/Ivacaftor: Data from the PROMISE study
Speaker: Sanghoon Park, MD – UT Southwestern
10:15 AM - 12:15 PM PDT

W26.4- Pregnancy and early parenthood does not have a detrimental impact on CF-health status in women under a dedicated CF Maternal Health Service in the elexacaftor/tezacaftor/ivacaftor era
Speaker: Amy Downes – Royal Brompton Hospital
10:15 AM - 12:15 PM PDT

W26.5- Screening for Diabetes and Pre-diabetes in Cystic Fibrosis Using a Non-fasting 50g 1 Hour Oral Glucose Challenge Test
Speaker: Monique D. Maher, MD – University of Colorado, Anschutz Medical Campus